Arrowhead Pharmaceuticals (NASDAQ:ARWR) Now Covered by Stifel Nicolaus

Investment analysts at Stifel Nicolaus initiated coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research report issued on Tuesday,Benzinga reports. The firm set a “buy” rating and a $98.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ price objective would indicate a potential upside of 32.24% from the company’s previous close.

Several other research analysts also recently issued reports on ARWR. Leerink Partners upped their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a “market perform” rating in a research report on Wednesday, June 17th. Morgan Stanley upgraded shares of Arrowhead Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $78.00 to $100.00 in a research report on Tuesday, April 21st. Wall Street Zen raised shares of Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Sanford C. Bernstein upped their target price on shares of Arrowhead Pharmaceuticals from $35.00 to $46.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. Finally, HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $88.17.

Arrowhead Pharmaceuticals Price Performance

Shares of ARWR stock opened at $74.11 on Tuesday. The stock’s fifty day simple moving average is $77.92 and its 200 day simple moving average is $69.42. Arrowhead Pharmaceuticals has a one year low of $14.30 and a one year high of $87.83. The firm has a market cap of $10.44 billion, a price-to-earnings ratio of -34.47 and a beta of 1.26. The company has a debt-to-equity ratio of 1.41, a current ratio of 6.23 and a quick ratio of 6.23.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, May 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.10) by $0.17. Arrowhead Pharmaceuticals had a negative return on equity of 55.09% and a negative net margin of 48.38%.The firm had revenue of $73.74 million during the quarter, compared to analyst estimates of $73.84 million. During the same period in the prior year, the company posted $2.75 earnings per share. The business’s revenue for the quarter was down 86.4% compared to the same quarter last year. On average, analysts expect that Arrowhead Pharmaceuticals will post -3 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Daniel Joseph Apel sold 13,095 shares of the business’s stock in a transaction that occurred on Wednesday, April 22nd. The shares were sold at an average price of $71.35, for a total transaction of $934,328.25. Following the completion of the sale, the chief financial officer directly owned 162,905 shares of the company’s stock, valued at $11,623,271.75. The trade was a 7.44% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider James C. Hamilton sold 10,000 shares of the stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $75.00, for a total transaction of $750,000.00. Following the completion of the transaction, the insider owned 226,958 shares in the company, valued at $17,021,850. This represents a 4.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 26,065 shares of company stock valued at $1,912,662. 3.60% of the stock is currently owned by insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in ARWR. Tsfg LLC acquired a new position in shares of Arrowhead Pharmaceuticals in the 4th quarter valued at $25,000. Optiver Holding B.V. boosted its position in shares of Arrowhead Pharmaceuticals by 83.8% in the 1st quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 186 shares during the last quarter. Versant Capital Management Inc grew its stake in shares of Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company’s stock worth $27,000 after purchasing an additional 248 shares during the period. Carolina Wealth Advisors LLC grew its stake in shares of Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 154 shares during the period. Finally, iSAM Funds UK Ltd bought a new stake in Arrowhead Pharmaceuticals in the third quarter valued at about $29,000. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.